U.S. Markets closed

Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.20000.0000 (0.00%)
At close: 9:41AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2000
Open0.2000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2000 - 0.2000
52 Week Range0.0500 - 0.2000
Volume1,000
Avg. Volume0
Market Cap3.693B
Beta (5Y Monthly)0.54
PE Ratio (TTM)25.00
EPS (TTM)0.0080
Earnings DateN/A
Forward Dividend & Yield0.00 (0.97%)
Ex-Dividend DateSep 29, 2020
1y Target EstN/A
  • PR Newswire

    Sihuan Pharmaceutical (0460.HK) Obtained the Exclusive Distribution Right for LipiVage(R) Fat Collection System in Greater China and South Korea

    Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460) is pleased to announce that Meiyen Laboratory Inc, an American subsidiary of the Group, has entered into a strategic cooperation with the American company Genesis Biosystems recently, and obtained the exclusive distribution right for its LipiVage® fat collection system in Greater China (mainland Ch

  • PR Newswire

    Sihuan Pharmaceutical (0460.HK): 'A Friend of Time' 2021 - The Turning-point Year

    Sihuan Pharmaceutical Holdings Group Ltd. plays a pivotal role in China's domestic medical industry and is a leading company for the development of the country's cardio-cerebral vascular prescription drugs. According to IMS data in 2018, Sihuan Pharmaceutical held a prominent place in China's national hospital prescription central cerebrovascular drug market with a share of nearly 8.3%.

  • PR Newswire

    Sihuan Pharmaceutical (0460.HK): Be a friend of time, 2021 is the year of turning point

    Sihuan Pharmaceutical Holdings Group Ltd. plays a pivotal role in the domestic medical industry. It is a leading company in China's CCV prescription drugs. According to IMS data in 2018, Sihuan Pharmaceutical is well-known on the national hospital prescription drug market share list, with its central cerebrovascular drug market share of nearly 8.3%.